Key result
14-day continuous ambulatory monitoring in hypertrophic cardiomyopathy increased the diagnostic yield for detecting nonsustained ventricular tachycardia by 2.7-fold compared to 48 hours (P<.001).
Why the study?
Although 48-hour ambulatory monitoring has been standard practice in HCM to detect NSVT, the diagnostic yield of continuous monitoring for up to 2 weeks compared with the initial 48 hours needed evaluation.
Does 14-day continuous ambulatory ECG monitoring improve the detection of non-sustained ventricular tachycardia compared to standard 48-hour monitoring in patients with hypertrophic cardiomyopathy?
Observational (n=236)
Does 14-day continuous ambulatory ECG monitoring improve the detection of non-sustained ventricular tachycardia compared to standard 48-hour monitoring in patients with hypertrophic cardiomyopathy?
Effect estimate: 2.7-fold greater
Absolute Event Rate: 48% vs 17.8%
p-value: p=<.001
Extended 14-day ambulatory ECG monitoring significantly increases the detection of both overall and higher-risk non-sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy compared to standard 48-hour monitoring.
May support extended monitoring for NSVT detection in HCM; leaves open effects on risk stratification and outcomes.
BACKGROUND: In hypertrophic cardiomyopathy (HCM), 48-hour ambulatory monitoring has been standard practice to detect nonsustained ventricular tachycardia (NSVT), a sudden death risk marker. Extended-wear ambulatory electrocardiographic (ECG) devices have more recently used for monitoring patients with HCM. OBJECTIVE: We aimed to evaluate NSVT burden identified with continuous ambulatory monitoring for up to 2 weeks compared with initial 48 hours. METHODS: 236 consecutive patients with HCM (49 ± 12 years) underwent 14-day continuous ambulatory monitoring (Zio XT, iRhythm Technologies, San Francisco, CA); diagnostic yield of NSVT compared for initial 48 hours vs extended for 14 days. RESULTS: Of the 236 patients, 114 (48%) had ≥ 1 runs of NSVT (median 2) over 14 days. Median length of NSVT was 7 beats (range: 3 to 67) at rates of 120 to 240 beats per minute (bpm) (median, 167 bpm). In 42 of the 114 patients (37%), initial NSVT occurred ≤ 48 hours and in 72 (63%) only during the extended monitoring period (3 to 14 days). Diagnostic yield for detecting NSVT over 14 days was 2.7-fold greater than ≤ 48 hours (P < .001). NSVT judged at higher risk (≥ 8 beats, > 200 bpm, ≥ 2 runs in consecutive 2-day period) was identified more frequently during extended monitoring, diagnostic yield over 14 days was 3-fold greater than ≤ 48 hours (P < .001). CONCLUSION: In HCM, NSVT episodes are frequent; however, in most patients, both NSVT and higher-risk NSVT were not detected during initial 48 hours and were confined solely to extended monitoring period. These data support additional clinical studies to evaluate the significance of NSVT on extended monitoring on sudden death risk in HCM.
No takes yet. Share an insight, caveat, or question.
Rowin et al. (2024) conducted an observational in Hypertrophic cardiomyopathy (n=236). 14-day continuous ambulatory monitoring vs. Initial 48 hours of monitoring was evaluated on Diagnostic yield of nonsustained ventricular tachycardia (NSVT) (2.7-fold greater, p=<.001). 14-day continuous ambulatory monitoring in hypertrophic cardiomyopathy increased the diagnostic yield for detecting nonsustained ventricular tachycardia by 2.7-fold compared to 48 hours (P<.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: